During the first quarter of 2017, Cortellis Competitive Intelligence had 1,073 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This meant a slight increase on the last quarter (1,022) and a similar volume on the same quarter for the previous 1 year (1,141). However, this quarter showed a significant augment in deals worth more than USD 0.5 billion on the last quarter (17 vs. 12). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestone, options and terminated deals of significance will also be presented, along with an early outlook on the next quarter's pharmaceutical licensing activity.
Keywords: Agreements; Deals; Licensing; Pharmaceutical industry.